Using millions of methylation segments, we developed DiffuCpG, a generative artificial intelligence (AI) diffusion model designed to solve the critical challenge of missing data in high-throughput methylation technologies. DiffuCpG goes beyond conven...
BACKGROUND: Tuberculosis (TB) remains a significant public health challenge, particularly in rural areas of high-burden countries like China. Active case finding (ACF) and timely treatment have been proven effective in reducing TB prevalence, but the...
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Apr 10, 2025
BACKGROUND & AIMS: Despite major advances in many fields of science and technology, pharmaceutical research and development continues to be inefficient across multiple diseases. Inflammatory bowel disease (IBD) trials are also subject to high failure...
Antibody discovery has been successful in designing and progressing molecules to the clinic and market based on largely empirical methods and human experience. The field is now transitioning from classical monospecific antibodies to innovative smart ...
INTRODUCTION: Over the past decades, the integration of modern technologies - such as electronic health records, cloud computing, and artificial intelligence (AI) - has revolutionized the collection, storage, and analysis of medical data in neurology...
Drug discovery before the 20th century often focused on single genes, molecules, cells, or organs, failing to capture the complexity of biological systems. The emergence of protein-protein interaction network studies in 2001 marked a turning point an...
Journal of the American Heart Association
Apr 10, 2025
Heart failure (HF) is a complex and varied condition that affects over 50 million people worldwide. Although there have been significant strides in understanding the underlying mechanisms of HF, several challenges persist, particularly in the accurat...
Journal of the American Heart Association
Apr 10, 2025
Nonspecific symptoms and other diagnostic challenges lead to underdiagnosis of cardiac amyloidosis (CA). Artificial intelligence (AI) could help address these challenges, but a summary of the performance of these tools is lacking. This narrative revi...
The future of drug discovery may be artificial intelligence (AI), but its present is not. AI is in its infancy in the field. To help AI mature, developers need nonproprietary, open, large, high-quality datasets to train and validate models, managed b...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.